Article
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Clinical lung cancer - 1 Mar 2021
Asahina Hajime, Tanaka Kentaro, Morita Satoshi, Maemondo Makoto, Seike Masahiro, Okamoto Isamu, Oizumi Satoshi, Kagamu Hiroshi, Takahashi Kazuhisa, Kikuchi Toshiaki, Isobe Takeshi, Sugio Kenji, Kobayashi Kunihiko
Abstract excerpt
BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated advanced non-small-cell lung cancer (NSCLC). However, disease progression occurs within 19 months of treatment. In the NEJ009 study, gefitinib plus carboplatin plus pemetrexed demonstrated significantly better progression-free and overall...
Topics
Join the communities discussing this publication.